Skip to main content
. 2023 Apr 6;59:101953. doi: 10.1016/j.eclinm.2023.101953

Table 2.

Characteristics of the clinical trials that included PRO.

Number of trials
Randomisation
 Randomised 26 (57.8%)
 Single-arm 19 (42.2%)
Blinding status
 Blinded 10 (22.2%)
 Open-label 35 (77.8%)
PRO related endpoint type
 Primary 1 (2.2%)
 Key secondary 2 (4.4%)
 Secondary or exploratory 42 (93.3%)